london euretina

This meeting has been awarded 20 CME credits

Security Notice

Please note that Kuoni are our only destination management company. Other venders indicating that are operating for the society should be ignored. We never use western union as a payment portal

Posters

Ranibizumab for the treatment of diabetic macular edema

Poster Details

First Author: I.Pastukh UKRAINE

Co Author(s):    N. Goncharova   N. Stremovskaya               0   0 0   0 0   0 0   0 0

Abstract Details



Purpose:

To present and analyze 2-years results of intravitreal (IVT) ranibizumab (Lucentis) in patients with diabetic macular edema (DME)

Setting:

Ophthalmology Department, Kharkov Medical Academy of Postgraduate Education, Ukraine

Methods:

Eight adult patients (16 eyes) with DME were assigned to receive 3 monthly IVT injections of 0.5 mg ranibizumab. During first year they received 4 and during second year - 4 additional injections. Assessment of visual acuity changes was the percentage of patients gaining of best-corrected visual acuity (BCVA), the central retinal thickness (CRT) measured by optical coherence tomography (OCT), we observed extent of intraocular hemorrhage, retinal vein diameter, and the incidence and severity of ocular and nonocular adverse events.

Results:

After 3months of follow-up all patients gained BCVA; mean BCVA improved on 10-35%. CRT showed a mean decrease of 45-55%. Most patients experienced decreases in the extent of retinal hemorrhage, retinal vein diameter. After 6 months of follow-up BCVA of all patients decreased on 5-15%. CRT showed a mean increase of 15-25% and our patients received additional injection. During first year patients of our group received 7 IVT injections of 0.5 mg ranibizumab. During second year our patients received 4 additional injections. Their BCVA and CRT remained steady. No patients experienced a severe adverse event that was attributed to ranibizumab.

Conclusions:

Ranibizumab is generally well-tolerated and may improve BCVA and decrease CRT. The improvements in BCVA and CRT observed during the initial monthly injection period (0 to 3 months) were possibly lost to the recurrence of macular edema, and patients received additional ranibizumab injections. During first year they received 7 and during second year – 4 ranibizumab injections The extent of retinal hemorrhage, retinal vein diameter continued to normalize for most of the patients to 6 months.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy